Literature DB >> 23360797

NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells.

Azat Garipov1, Hua Li, Benjamin G Bitler, Roshan J Thapa, Siddharth Balachandran, Rugang Zhang.   

Abstract

Epithelial ovarian cancer (EOC) accounts for the most gynecologic malignancy-associated deaths in the United States. Enhancer of zeste homolog 2 (EZH2), which silences gene expression through generating trimethylation on lysine 27 residue of histone H3 (H3K27Me3), is often overexpressed in EOCs and has been suggested as a therapeutic target. However, the mechanism underlying EZH2 overexpression in EOCs is unknown. Here, we show that EZH2 is upregulated at the transcription level, and two CCAAT boxes in the proximal regions of the human EZH2 gene promoter are critical for its transcription in EOC cells. Indeed, NF-YA, the regulatory subunit of the CCAAT-binding transcription factor NF-Y, is expressed at higher levels in human EOCs than in primary human ovarian surface epithelial (HOSE) cells. In addition, there is a positive correlation between expression of NF-YA and EZH2 in EOCs. Notably, high NF-YA expression predicts shorter overall survival in patients with EOCs. The association of NF-YA with the promoter of the human EZH2 gene is enhanced in human EOC cells compared with primary HOSE cells. Significantly, knockdown of NF-YA downregulates EZH2, decreases H3K27Me3 levels, and suppresses the growth of human EOC cells both in vitro and in a xenograft mouse model. Notably, NF-YA knockdown induces apoptosis of EOC cells and ectopic EZH2 expression partially rescues apoptosis induced by NF-YA knockdown. Together, these data reveal that NF-Y is a key regulator of EZH2 expression and is required for EOC cell proliferation, thus representing a novel target for developing EOC therapeutics. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23360797      PMCID: PMC3631279          DOI: 10.1158/1541-7786.MCR-12-0661

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  34 in total

1.  Transcription factor NF-Y induces apoptosis in cells expressing wild-type p53 through E2F1 upregulation and p53 activation.

Authors:  Aymone Gurtner; Paola Fuschi; Fabio Martelli; Isabella Manni; Simona Artuso; Giacoma Simonte; Valeria Ambrosino; Annalisa Antonini; Valentina Folgiero; Rita Falcioni; Ada Sacchi; Giulia Piaggio
Journal:  Cancer Res       Date:  2010-10-15       Impact factor: 12.701

2.  MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes.

Authors:  S Fujii; K Tokita; N Wada; K Ito; C Yamauchi; Y Ito; A Ochiai
Journal:  Oncogene       Date:  2011-04-18       Impact factor: 9.867

3.  The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

4.  NF-Y is essential for expression of the proapoptotic bim gene in sympathetic neurons.

Authors:  R Hughes; M Kristiansen; I Lassot; S Desagher; R Mantovani; J Ham
Journal:  Cell Death Differ       Date:  2010-12-17       Impact factor: 15.828

5.  Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.

Authors:  Hua Li; Qi Cai; Andrew K Godwin; Rugang Zhang
Journal:  Mol Cancer Res       Date:  2010-11-29       Impact factor: 5.852

6.  Regulation of tumor angiogenesis by EZH2.

Authors:  Chunhua Lu; Hee Dong Han; Lingegowda S Mangala; Rouba Ali-Fehmi; Christopher S Newton; Laurent Ozbun; Guillermo N Armaiz-Pena; Wei Hu; Rebecca L Stone; Adnan Munkarah; Murali K Ravoori; Mian M K Shahzad; Jeong-Won Lee; Edna Mora; Robert R Langley; Amy R Carroll; Koji Matsuo; Whitney A Spannuth; Rosemarie Schmandt; Nicholas B Jennings; Blake W Goodman; Robert B Jaffe; Alpa M Nick; Hye Sun Kim; Eylem Ozturk Guven; Ya-Huey Chen; Long-Yuan Li; Ming-Chuan Hsu; Robert L Coleman; George A Calin; Emir B Denkbas; Jae Yun Lim; Ju-Seog Lee; Vikas Kundra; Michael J Birrer; Mien-Chie Hung; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

7.  A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

Authors:  Samuel C Mok; Tomas Bonome; Vinod Vathipadiekal; Aaron Bell; Michael E Johnson; Kwong-kwok Wong; Dong-Choon Park; Ke Hao; Daniel K P Yip; Howard Donninger; Laurent Ozbun; Goli Samimi; John Brady; Mike Randonovich; Cindy A Pise-Masison; J Carl Barrett; Wing H Wong; William R Welch; Ross S Berkowitz; Michael J Birrer
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

8.  CCAAT binding factor (CBF) binding mediates cell cycle activation of topoisomerase IIalpha. Conventional CBF activation domains are not required.

Authors:  Qianghua Hu; Chitralekha Bhattacharya; Sankar N Maity
Journal:  J Biol Chem       Date:  2002-07-30       Impact factor: 5.157

9.  Expression levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple cancers.

Authors:  Kazunori Yamanaka; Shinji Mizuarai; Tomohiro Eguchi; Hiraku Itadani; Hiroshi Hirai; Hidehito Kotani
Journal:  Genomics       Date:  2009-06-25       Impact factor: 5.736

10.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

View more
  28 in total

Review 1.  Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.

Authors:  Haiqi Lu; Guangliang Li; Chenyi Zhou; Wei Jin; Xiaoling Qian; Zhuo Wang; Hongming Pan; Hongchuan Jin; Xian Wang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

Review 2.  Diverse involvement of EZH2 in cancer epigenetics.

Authors:  Pamela Völkel; Barbara Dupret; Xuefen Le Bourhis; Pierre-Olivier Angrand
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

Review 3.  Emerging EZH2 Inhibitors and Their Application in Lymphoma.

Authors:  Jennifer K Lue; Jennifer E Amengual
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 4.  Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Authors:  Bayley A Jones; Sooryanarayana Varambally; Rebecca C Arend
Journal:  Mol Cancer Ther       Date:  2018-03       Impact factor: 6.261

Review 5.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

6.  Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells.

Authors:  Huan-Tian Zhang; Dabao Zhang; Zhen-Gang Zha; Chang-Deng Hu
Journal:  Biochim Biophys Acta       Date:  2014-10-02

7.  Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.

Authors:  Xuejun Tian; Ashley Pelton; Ali Shahsafaei; David M Dorfman
Journal:  Mod Pathol       Date:  2016-06-10       Impact factor: 7.842

8.  A pan-cancer modular regulatory network analysis to identify common and cancer-specific network components.

Authors:  Sara A Knaack; Alireza Fotuhi Siahpirani; Sushmita Roy
Journal:  Cancer Inform       Date:  2014-10-28

9.  Live cell dynamics of the NF-Y transcription factor.

Authors:  David G Priest; Andrea Bernardini; Jieqiong Lou; Roberto Mantovani; Elizabeth Hinde
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.379

10.  Regulation and Role of EZH2 in Cancer.

Authors:  Hirohito Yamaguchi; Mien-Chie Hung
Journal:  Cancer Res Treat       Date:  2014-07-15       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.